Creating new targeted therapies for advanced prostate cancer
Official title: Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype
Funded at University of California, San Francisco · NIH-11062409 · Data updated 2026-11-12
This study is testing a new type of treatment for metastatic prostate cancer that uses special antibodies to target cancer cells more effectively, and it aims to help patients get better results than with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $561,495 |
| NIH project number | 5R01CA289874-02 |
| Project ID | NIH-11062409 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with metastatic prostate cancer, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have the specific tumor antigens targeted by the bispecific ADCs may not benefit from this research.
What this research studies
This research focuses on developing innovative bispecific antibody-drug conjugates (ADCs) to treat metastatic prostate cancer. By targeting multiple tumor cell surface antigens simultaneously, the approach aims to enhance the effectiveness of treatment and improve drug delivery to cancer cells. The study builds on previous findings that identified specific antigens, such as CD46 and B7-H3, which are consistently expressed in prostate cancer. Patients may benefit from this targeted therapy, which could lead to better outcomes compared to existing treatments.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results with similar bispecific antibody approaches in other cancers, indicating potential for success in this novel application.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Liu, Bin — University of California, San Francisco
- Study coordinator: Liu, Bin
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.